BioArctic AB (STO:BIOAB), a Swedish research-based biopharmaceutical company, announced on Wednesday that the first clinical study with ABBV-0805 has started in the US.
Reportedly, biopharmaceutical company AbbVie Inc (NYSE:ABBV) is responsible for the clinical development of ABBV-0805. This phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805.
According to the company, ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed by AbbVie from BioArctic in December 2018. This antibody is being evaluated as a disease modifying treatment for Parkinson's disease.
ABBV-0805 is a result of a strategic research alliance between BioArctic and AbbVie focused on the development of a potential immunotherapy for Parkinson's disease.
BioArctic is focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury.
DNAnexus Appoints Scott Gibson as Chief Financial Officer
Takeda Touts New Exploratory Data from VARSITY Ulcerative Colitis Biologic Study
Pack Health names Kelly Brassil, PhD, RN, as director of Medical Affairs
BioArctic expects EUR15m payment from Eisai for start of BAN2401 Clarity AD study
Oncopeptides to apply for melflufen's accelerated approval with the US FDA for multiple myeloma
DelMar Pharmaceuticals adds three oncologists to Scientific Advisory Board
AbbVie withdraws phase three trial of depatuxizumab mafodotin
Infant Bacterial Therapeutics announces agreement by US FDA on design of phase III study